Glenmede Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History

Glenmede Trust’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,588	Closed	-$408K	–	1308
2021 Q1	$408K	Buy	3,588 +43	+1%	+$5.85K	﹤0.01%	901
2020 Q4	$490K	Buy	3,545 +371	+12%	+$44K	﹤0.01%	848
2020 Q3	$260K	Buy	3,174 +3,160	+22,571%	+$262K	﹤0.01%	960
2020 Q2	$1K	Hold	14	–	–	﹤0.01%	2359
2020 Q1	$0	Hold	14	–	–	﹤0.01%	3050
2019 Q4	$0	Hold	14	–	–	﹤0.01%	3105
2019 Q3	$0	Hold	14	–	–	﹤0.01%	3095
2019 Q2	$0	Hold	14	–	–	﹤0.01%	3149
2019 Q1	$0	Hold	14	–	–	﹤0.01%	3157
2018 Q4	$0	Buy	+14	New	+$765	﹤0.01%	3073
2016 Q4	–	Sell	-14	Closed	–	–	2592
2016 Q3	$0	Buy	+14	New	+$894	﹤0.01%	2661
2016 Q1	–	Sell	-24	Closed	-$2K	–	2704
2015 Q4	$2K	Hold	24	–	–	﹤0.01%	2466
2015 Q3	$2K	Hold	24	–	–	﹤0.01%	2519
2015 Q2	$2K	Sell	24 -33	-58%	-$2.56K	﹤0.01%	2456
2015 Q1	$3K	Buy	+57	New	+$3.17K	﹤0.01%	2328

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Glenmede Trust's RARE Position: Q2 2021 in Review

Glenmede Trust sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 3,588 shares — an estimated $408K sold.

Glenmede Trust first reported a position in RARE in Q1 2015 and held it in 15 quarters. The position peaked at $490K in Q4 2020. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Glenmede Trust reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Glenmede Trust sold 3,588 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $408K.
Glenmede Trust first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 15 quarters.
Glenmede Trust's Ultragenyx Pharmaceutical position peaked at $490K in Q4 2020.
241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Glenmede Trust's 13F filing for Q2 2021, filed 16 Aug 2021.